complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III MM and at least one lytic lesion. 189 , 190 Zoledronic acid has equivalent benefits. 191 Results from the study conducted by Zervas et
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
radiation therapy to boney sites. Early studies of pamidronate to prevent skeletal-related events confirmed its value in decreasing those events without direct impact on breast cancer or overall survival. 24 Subsequently, zoledronic acid and the monoclonal
James L. Mohler
skeletal-related events (zoledronic acid and denosumab). 18 Finally, men who develop castration-recurrent prostate cancer have new opportunities for therapy that extend beyond secondary ADT. Sipuleucel-T was shown to extend life expectancy in men with
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead and Rashmi Kumar
Similarly, zoledronic acid seems to have a different effect in patients with high versus low estrogen environments (postmenopausal vs premenopausal patients). In the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) trial, for patients
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff
advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group . J Clin Oncol 1999 ; 17 : 846 – 854 . 214 Berenson JR Rosen LS Howell A . Zoledronic acid reduces skeletal
Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes and Vered Stearns
Schippinger WL . Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [abstract
James L. Mohler
. James ND Sydes MR Clarke NW . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial . Lancet
James L. Mohler
. 8. James ND Sydes MR Clarke NW . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Somasundaram Subramaniam, Jason A. Zell and Pamela L. Kunz
temozolomide in hopes of achieving tumor regression. He also received zoledronic acid for prophylaxis of skeletal events. He developed back pain, for which he had radiation therapy and vertebroplasty to the T12 vertebral body. He had stable disease through 7
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars
breast cancer in bone to prevent bone fractures, bone pain requiring radiation therapy, spinal cord compression, and hypercalcemia (skeletal related events [SREs]). 279 – 281 The bisphosphonates zoledronic acid or pamidronate have been used for this
